

## AM095 (free acid)

Catalog No: tcsc1129



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg



### Specifications

**CAS No:**

1228690-36-5

**Formula:**

$C_{27}H_{24}N_2O_5$

**Pathway:**

GPCR/G Protein

**Target:**

LPL Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 67.3 mg/mL (147.43 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

456.49


## Product Description

AM095 (free acid) is a potent **LPA1** receptor antagonist with **IC<sub>50</sub>** values of 0.98 and 0.73  $\mu\text{M}$  for recombinant human or mouse LPA1 respectively.

IC50 & Target: IC50: 0.98  $\mu\text{M}$  (human LPA1), 0.73  $\mu\text{M}$  (mouse LPA1)

**In Vitro:** AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA1. The  $\text{IC}_{50}$  for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023  $\mu\text{M}$ , respectively<sup>[1]</sup>. AM095 reduces LPA-induced vasorelaxation by appr 90% at 10  $\mu\text{M}$  as compared to vehicle control<sup>[2]</sup>. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 ( $\text{IC}_{50}$ =778 nM) and human A2058 melanoma cells ( $\text{IC}_{50}$ =233 nM)<sup>[3]</sup>.

**In Vivo:** Pharmacological antagonism of LPA1 with AM095 significantly attenuates bleomycin-induced dermal fibrosis<sup>[1]</sup>. AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. AM095 dose-dependently reduces LPA-stimulated histamine release. AM095 attenuates bleomycin-induced increases in collagen, protein, and inflammatory cell infiltration in bronchalveolar lavage fluid. AM095 decreases kidney fibrosis in a mouse unilateral ureteral obstruction model<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!